Taconic Biosciences News

Taconic Biosciences News is your source for current and relevant news on how animal models are being used to drive drug discovery. Use the links below to explore exciting announcements from Taconic via Press Releases, Taconic’s press coverage in Publications and Media, and critical scientific insights within Industry News.

The role of immunodeficient animal models in advancing immuno-oncology research

Drug Discovery World features Dr. Michael Seiler as the author and he discusses immunodeficient models, advances in human immune system models, and immuno-oncology studies and applications: "From inbred wild-type to more advanced genetically-engineered strains, mouse models enable researchers to gain important insights into the complex biological underpinnings of human cancer. Among those, spontaneous and genetically engineered immunodeficient strains can be administered in both primary human tumour tissue...

Read More

Tipping the Balance in Microbiome Standoffs

Genetic Engineering & Biotechnology spotlights Taconic Biosciences, specifically with information about the human microbiome: "The Human Microbiome May Dispose Us toward Health or Illness On The Basis Of Tiny Shifts in Microbial Subpopulations. The human body is immersed in the microbial world; our microbiota takes care of us. Yet the microbiota is complex, and much remains unknown about its composition and function. Moreover, microbiota are subject to...

Read More

The Microbiome: A New Research Tool

PharmaVOICE features Taconic's Product Manager Jennifer Phelan who speaks openly about her knowledge of the microbiome: "Our bodies are home to trillions of microbes, including bacteria, fungi, and viruses. These microbes are essential; they help digest food, produce certain vitamins, and regulate the immune system. Until recently, little was known about these microbes, but advances in DNA sequencing are making it possible to analyze the human microbiome....

Read More

Taconic Biosciences Launches huNOG-EXL Mouse Model

Model Will Transform Immuno-Oncology, Allergy and Inflammation Research Hudson, NY - February 2, 2016 - Taconic Biosciences, a leading provider of genetically modified mouse models and associated services to researchers worldwide, announced it has launched the huNOG-EXL, an extended lineage mouse model that will greatly improve immuno-oncology, allergy and inflammation research. Available exclusively from Taconic, the huNOG-EXL incorporates an engrafted human immune system to recapitulate myeloid lineages...

Read More

CRISPR-Cas9: The bold, new, fast, inexpensive frontier of gene editing

The Journal of Precision Medicine highlights Taconic's Dr. Michael Seiler who outlines how gene editing has progressed in recent years: "If Helen of Troy possessed the face that launched a thousand ships, it is not a stretch to say that the publication in the summer of 2012 of "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity" in the journal Science by Jennifer Doudna and Emmanuelle Charpentier,...

Read More

The Brain: The Decade Ahead

PharmaVOICE features Taconic because of their expertise on CNS disorders and research: "The three-pound organ -- made up of more than 100 billion nerves -- that serves as the center of the nervous system is one of the most complex parts of the human body. Only recently have researchers and scientists begun to understand the brain and what can go wrong. This special forum kicks off a...

Read More

GEN Roundup: Optimizing Your ADME/Tox Operations

Genetic Engineering & Biotechnology specifies best practices for improving ADME/Tox efforts: "Early-Drug Screening Is Due For Review - Before a new prescription medicine gains marketing approval, it typically goes through a development process that lasts at least a decade. Moreover, according to the Tufts Center for the Study of Drug Development, the costs can exceed $2.5 billion." Read the complete article at: Genengnews.com...

Read More

The increasing impact of precision research models on drug discovery and development

Drug Discovery World features Taconic Biosciences outlining the advancements made of genetically engineered models: "In a Challenges and Opportunities report issued by the US Food and Drug Administration (FDA), it was noted that the inability to predict lack of effectiveness and safety problems before human testing or early in clinical trials dramatically escalates costs of drug development. According to the FDA, drug developers could save $100 million...

Read More

Tumor Models Bridge Mouse-Human Gap

Genetic Engineering & Biotechnology details trends in animal and humanized models available at Taconic: "Revamped Allograft and Innovative Xenograft Models Can Reduce the Risks of Late-Stage Clinical Trials and Increase the Odds of Translational Success - Precision medicine is all about the two T's—targets and treatments—targets that emerge from analyses of patient-specific information, and treatments that hit these targets. Both T's, however, pose difficulties. All too often,...

Read More

New Guidelines Involve the Testing Done on Animal Models

Genetic Engineering & Biotechnology News details safety testing done with Taconic models: "Prior to obtaining regulatory approval for use in humans, novel pharmaceutical drugs require extensive safety testing. Guidelines regarding testing strategies are issued by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), an agreement established in 1991 between the regulatory authorities in the United States, European Community (EC),...

Read More